Johnson & Johnson Announces $1B Cell Therapy Manufacturing Facility

February 13, 2026

Johnson & Johnson, an AABB corporate partner, recently announced plans to build a $1 billion next-generation cell therapy manufacturing facility in Pennsylvania. The site will expand the company’s U.S. cell therapy production capacity to support treatments for cancer, immune-mediated and neurological diseases. The company expects the facility to support more than 500 biomanufacturing jobs when fully operational.